Key Points
- Director Elisabeth Bjork sold 52,500 Pharvaris shares at an average price of $37.89, generating approximately $1.99 million and reducing her holdings by 77.59% to 15,167 shares.
- Pharvaris shares opened at $36.02, with a market capitalization of about $2.36 billion; the company reported a quarterly loss of $0.81 per share, below the $0.75 consensus estimate.
- Analysts remain broadly positive, with 13 Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $59.87.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $38.56, for a total transaction of $558,850.08. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at $404,880. This represents a 57.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Robert Glassman also recently made the following trade(s):
- On Tuesday, September 15th, Robert Glassman sold 8,667 shares of Pharvaris stock. The stock was sold at an average price of $38.27, for a total value of $331,686.09.
- On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total value of $300,400.00.
Pharvaris Price Performance
Shares of PHVS stock opened at $36.02 on Tuesday. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The stock's fifty day moving average price is $35.39 and its 200 day moving average price is $31.82. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
PHVS has been the topic of several recent research reports. Oppenheimer reaffirmed an "outperform" rating and issued a $75.00 price objective on shares of Pharvaris in a report on Tuesday, September 8th. Wells Fargo & Company raised their target price on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a report on Wednesday, September 9th. Leerink Partners boosted their target price on shares of Pharvaris from $50.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a report on Wednesday, September 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price target on shares of Pharvaris in a research report on Monday, September 14th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $59.87.
Check Out Our Latest Stock Report on PHVS
Hedge Funds Weigh In On Pharvaris
Several institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of Pharvaris in the 2nd quarter valued at $41,000. CoreCap Advisors LLC acquired a new stake in Pharvaris during the second quarter valued at $93,000. Public Employees Retirement System of Ohio purchased a new position in Pharvaris in the second quarter valued at $196,000. Algert Global LLC purchased a new position in Pharvaris in the second quarter valued at $238,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Pharvaris in the second quarter worth about $273,000.
Pharvaris News Roundup
Here are the key news stories impacting Pharvaris this week:
- Negative Sentiment: Director Johannes Gerardus Chri Schikan sold 200,000 shares for approximately $7.0 million, reducing his ownership by 63.46% to 115,167 shares. SEC filing
- Negative Sentiment: President Peng Lu sold 100,000 shares for $3.5 million, cutting her position by 60.62% to 64,953 shares. SEC filing
- Negative Sentiment: Director Elisabeth Bjork sold 52,500 shares for approximately $2.0 million, reducing her holdings by 77.59% to 15,167 shares. SEC filing
- Negative Sentiment: Insider Anne Lesage sold 20,000 shares for $765,400, a 21.28% reduction in her position, leaving her with 73,969 shares. SEC filing
- Negative Sentiment: Director Robert Glassman sold 14,493 shares for approximately $558,850, reducing his holdings by 57.99% to 10,500 shares. SEC filing
About Pharvaris
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
